Section Arrow
Quote
NXTC.NASDAQ
- NextCure Inc
Quotes are at least 15-min delayed:2026/04/15 11:05 EDT
Regular Hours
Last
 12.85
+0.08 (+0.63%)
Day High 
12.85 
Prev. Close
12.77 
1-M High
13.5 
Volume 
5.17K 
Bid
12.61
Ask
12.95
Day Low
12.54 
Open
12.54 
1-M Low
8.63 
Market Cap 
45.47M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 11.32 
20-SMA 10.89 
50-SMA 11.91 
52-W High 15.7399 
52-W Low 4.0944 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-19.65/-3.47
Enterprise Value
49.61M
Balance Sheet
Book Value Per Share
9.81
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.7226+0.4078+129.54%-- 
LIMNLiminatus Pharma Inc0.2085+0.0287+15.96%-- 
ALLOAllogene Therapeutics1.945-0.335-14.69%-- 
CUECue Biopharma0.5556+0.1176+26.85%-- 
LNAILunai Bioworks Inc.0.2934-0.0454-13.40%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.